Sareum Holdings plc announced this morning that it has submitted an application for Clinical Trial Authorisation (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the development of SDC-1801. We have published research on this which is attached and a snapshot of the research is below. Sareum Holdings plc announced this morning that it has submitted an application for Clinical Trial Authorisation (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (M ....